Lifecome Biochemistry Co., Ltd. Class A

As of June 30, 2026, Lifecome Biochemistry Co., Ltd. Class A carries a market capitalization of 3.43B, placing it among publicly traded companies globally. Its enterprise value stands at 3.70B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Lifecome Biochemistry Co., Ltd. Class A has 155.42M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 6.75, and the price-to-book ratio stands at 48.39.

These figures are as of June 30, 2026. The EV/Sales ratio of 7.31 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 3.70B versus a market cap of 3.43B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Lifecome Biochemistry Co., Ltd. Class A maintains a current ratio of 0.37, meaning it holds 0.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 440.71, indicating elevated leverage, while an interest coverage ratio of -1.73 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -7.22, reflecting losses generated across the asset base. The company generates approximately 796,193.28 in revenue per employee across its workforce of 636.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 4.45 indicates how many times Lifecome Biochemistry Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Lifecome Biochemistry Co., Ltd. Class A recorded 903,908.95 in income tax expense. The company reported a pretax loss of -78.05M and -78.52M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, Lifecome Biochemistry Co., Ltd. Class A's stock has declined approximately 31.21% over the past 52 weeks. The 50-day moving average sits at 22.50, while the 200-day moving average is 30.60.

Over the twelve months ended June 30, 2026, Lifecome Biochemistry Co., Ltd. Class A generated 506.58M in revenue and converted that into -78.52M in net income, yielding earnings per share of -0.51. EBITDA reached -67.63M, while operating income came in at -1.64M.

As of June 30, 2026, Lifecome Biochemistry Co., Ltd. Class A holds 51.40M in cash and equivalents against 318.86M in total debt, resulting in a net debt position of 135.10M. Total book value stands at 70.95M, with working capital of -346.90M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Lifecome Biochemistry Co., Ltd. Class A posted a gross margin of 13.78, reflecting its pricing power and cost economics. The operating margin of -0.32 and net profit margin of -15.50 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Lifecome Biochemistry Co., Ltd. Class A paid dividends of 0.30 per share. The dividend payout ratio of -58.16 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield is negative at -5.19, meaning Lifecome Biochemistry Co., Ltd. Class A raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Lifecome Biochemistry Co., Ltd. Class A's most recent stock split took place on May 28, 2020 with a 10:13 split ratio.

As of June 30, 2026, Lifecome Biochemistry Co., Ltd. Class A has an Altman Z-Score of 1.84, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.